D Molecular Therapeutics, Inc.’s FDMT share price has surged by 5.88%, which has investors questioning if this is right time ...

4D Medical raises $8.4 million in an oversubscribed share purchase plan With Opthea shares suspended, investors rough up other phase III stage biotechs Immutep doses first patient in its phase III ...